Ergomed is an international clinical development company with a specialised Rare Disease Division development division. Ergomed has successfully planned, managed and completed clinical trials in Orphan indications worldwide in various Oncology, Hematology, Metabolic Diseases and also other indications.
We have a proven ability to access patients with rare diseases and improve recruitment through our unique Study Site Management model and our close collaborations with medical networks. Ergomed’s medical experience and geographic presence provide access to ‘hard-to-find’ rare disease patient populations. Ergomed provides regulatory and scientific expertise which helps to ensure the best designs for rare disease clinical programs and registries.
The company offers standard clinical trial management contracts as well as investment in codevelopment partnerships which share the risks and rewards of clinical development. Ergomed has global operations with the unique advantage of a well-established presence in the Middle East and North Africa (MENA) region, India and Latin America where we work closely with designated Centers of Excellence.
Ergomed is headquartered in UK, and has offices in the Germany, Italy, Spain, Poland, Croatia, Bosnia and Herzegovina, Serbia, Switzerland, Russia, Ukraine, India, UAE, KSA and the USA. Ergomed has a track record of delivering extremely high quality data within agreed budgets. Ergomed’s approach to clinical research and site management, with clinical site coordinators resident in major sites, ensures fast and effective patient recruitment, reducing the time and costs of clinical trials. As a result, a significant portion of ongoing trials come from repeat business from satisfied clients and through referrals from existing customers.
ERGOMED would like to meet with you at the congress to discuss how we can help you with your planned drug development activities. We have international experience in the issues facing companies in the rare disease area and our proven expertise in patient recruitment in difficult studies makes us an ideal partner. We can also offer investment in selected studies through our unique co-development model.
Ergomed's Rare Disease team will be attending the congress and would be very interested in meeting with you and learning about your activities and how we may be able to help.